MedKoo product information:

ME-143   

Description of ME-143 (NV-143): ME-143 is a derivative of triphendiol and is a highly potent, pan acting ant-cancer.  It is active against every melanoma cell line tested to date and is able to sensitize melanoma cell lines to the standard of care drug, dacarbazine, and members of the platinum drug scaffold.  Proof of concept studies in animal models of melanoma have demonstrated that orally delivered ME-143 retards tumour proliferation.  The ME-143 mechanism of action in melanoma has not been fully elucidated.  ME-143 is non-clastogenic.   

Current developer:  Novogen (Australia) and Marshall Edwards.

ME-143 is the lead oncology drug candidate from Marshall Edwards. In pre-clinical studies, ME-143 has demonstrated potent activity against a number of tumor cell lines, including breast, colorectal and ovarian. In addition to broad single-agent activity, ME-143 has also shown an ability to enhance the cytotoxic effects of chemotherapy in pre-clinical studies. Marshall Edwards owns exclusive worldwide rights to ME-143.